BMC cancer · 2025
The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Liqiao, Xu Jieli, Li Jialin, Ji Ke, Zhang Ji, Wu Xiaojiang, Zhou Kai, Tang Jiatian, Wu Yan, Wang Anqiang, Bu Zhaode
Аннотация
BACKGROUND: Advanced hepatoid adenocarcinoma of stomach still lacks effective and standardized treatment options. This study aims to explore the therapeutic value of translational therapy in advanced hepatoid adenocarcinoma of stomach.
METHODS: We conducted a retrospective analysis of 37 patients with advanced hepatoid adenocarcinoma of stomach who successfully underwent translational therapy followed by surgical intervention between October 2009 and October 2024. Through survival analysis and Cox regression, we identified the clinicopathological factors that significantly impact patient prognosis.
RESULTS: The median survival time of 37 patients was 39.0 months. 70.3% of patients achieved R0 resection, with an average OS 93.8 months and a 5-year survival rate of 64.4%. And 10.8% of patients achieved pathological complete remission, with an average OS of 65.7 months and a 5-year survival rate of 100%. Additionally, radical surgery, pM stage, cytology, and surgery type were identified as independent risk factors influencing the prognosis of patients.
CONCLUSION: Translational therapy is a promising strategy for patients with initially unresectable advanced hepatoid adenocarcinoma of stomach. Achieving R0 resection and attaining pathological complete remission are crucial milestones in improving patient prognosis.
METHODS: We conducted a retrospective analysis of 37 patients with advanced hepatoid adenocarcinoma of stomach who successfully underwent translational therapy followed by surgical intervention between October 2009 and October 2024. Through survival analysis and Cox regression, we identified the clinicopathological factors that significantly impact patient prognosis.
RESULTS: The median survival time of 37 patients was 39.0 months. 70.3% of patients achieved R0 resection, with an average OS 93.8 months and a 5-year survival rate of 64.4%. And 10.8% of patients achieved pathological complete remission, with an average OS of 65.7 months and a 5-year survival rate of 100%. Additionally, radical surgery, pM stage, cytology, and surgery type were identified as independent risk factors influencing the prognosis of patients.
CONCLUSION: Translational therapy is a promising strategy for patients with initially unresectable advanced hepatoid adenocarcinoma of stomach. Achieving R0 resection and attaining pathological complete remission are crucial milestones in improving patient prognosis.